Market News / Story
Curasight (CURAS) Resumes Glioblastoma Phase I After Protocol OK
·
Curasight can resume enrolment in its phase I glioblastoma trial after approval of an amended protocol and keeps topline data timing in H1 2027. Material Details #DetailAI Analyst View1Enrollment resumes in phase I trialRemoves a regulatory overhang and restarts value-driving clinical progress.2Protocol amendment approvedRegulatory green light lowers near-term trial execution risk.3Topline data guided H1 2027Timeline intact; anchors catalysts and funding runway…